Studies on the immune response in patients with chronic renal failure 3. Immune response in patients on continuous ambulatory peritoneal dialysis

• Published in: Journal of Japanese Society for Dialysis Therapy Vol. 16; no. 4; pp. 225 - 229
• Main Author: Morikawa, Yoji
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society for Dialysis Therapy 31.08.1983
• Subjects: CAPD; chronic renal failure; guanidino compounds; hemofiltration; immunity
• ISSN: 0288-7045; 1884-6203
• DOI: 10.4009/jsdt1968.16.225

The alteration of the immune response in patients with chronic renal failure (CRF) on hemodialysis (HD) and hemofiltration (HF) was previously reported. In this study, PHA-induced blastoid transformation of lymphocytes from the patients undergoing continuous ambulatory peritoneal dialysis (CAPD) was examined in the whole blood culture and the ratio of 3H-thymidine incorporation into the lymphocytes stimulated with and without phytohemagglutinin (PHA) was calculated as stimulation index (SI). Serum concentration of guanidino compounds was concomitantly measured. These results were compared with that of HD and HF patients. The SI was 60.27±22.05 for the HF patients, 57.92±37.96 for the CAPD patients and 39.80±21.70 for the HD patients, is due order. Although the value for the HF patients was significantly higher than that for the HD patients (p<0.02), there was no significant difference between the CAPD and HF or HD patients. The serum concentration of methylguanidine (MG) was 23.92±11.05μg/dl, 19.46±19.93μg/dl and 38.97±18.83μg/dl for the HF, CAPD and HD patients, respectively. The value for the HD patients was significantly higher than that for the HF patients (p<0.05) and the CAPD patients (p<0.01), but there was no significant difference between the HF and CAPD patients. The SI and serum concentration of MG for the CRF patients were inversely correlated. From these results, MG can be considered to be one of the inhibitory substances against the cellular immunity in uremic plasma. Therefore, HF seems to be the most available mode of therapy, in that HF better improves the cellular immunity of CRF patients by reducing MG.